Does Medicare Advantage Cover Zetia (Ezetimibe)?

Ezetimibe is a cholesterol absorption inhibitor sold under the brand name Zetia (now generic since December 2016) and in fixed-dose combination with simvastatin. It is FDA-approved as an adjunct to diet, alone or with a statin, to lower LDL cholesterol in primary hyperlipidemia, and as monotherapy in homozygous sitosterolemia. It is not the same drug class as statins (HMG-CoA reductase inhibitors), PCSK9 inhibitors, or bempedoic acid, even though all four are used to lower LDL.

Direct answer: Most Medicare Advantage plans that include Part D drug coverage (MA-PD plans) cover generic ezetimibe, usually on a preferred generic tier with a low copay, without prior authorization. Brand-name Zetia is covered far less consistently, is more often placed on a higher brand tier, and is more likely to require prior authorization or a "generic first" step. The specific tier, copay, and prior authorization rules vary by plan and change from year to year, so a beneficiary needs to check their own plan's current formulary rather than assume coverage terms from a general description.

The useful question for most readers is not "does Medicare cover ezetimibe" but "which formulation does my plan cover, on what tier, and what documentation does my prescriber need to submit if it doesn't."

What is established and what is not

Established: CMS requires every Part D and MA-PD sponsor to cover at least two drugs in most therapeutic categories, ezetimibe's generic status since 2016 has substantially lowered its retail price compared with the brand, and federal regulation sets fixed timelines for coverage determinations and appeals (standard and expedited) under 42 CFR Part 423. Manufacturer copay cards cannot be used by anyone enrolled in a federal health program, including Medicare Advantage and Part D, under the federal anti-kickback statute.

Plausible but plan-dependent: Generic ezetimibe is commonly, but not universally, placed on a preferred generic tier with no prior authorization. Actual tier placement, copay amount, and prior authorization or step-therapy triggers differ by carrier, plan, and plan year, and no single number applies to "Medicare Advantage" as a whole.

Not established from the evidence available here: Exact percentages of plans that impose prior authorization on generic ezetimibe, the precise effect size of ezetimibe added to statin therapy on cardiovascular outcomes, and specific appeal overturn-rate statistics are cited in various secondary sources but are not verified here against a primary CMS formulary dataset or the original outcomes trial publication. Treat any specific percentage in this space as something to confirm at the plan level or against the primary source before quoting it to a patient.

How Medicare Advantage handles the two formulations differently

Generic ezetimibe tends to sit on Tier 1 (preferred generic) or Tier 2 (generic) on MA-PD formularies, which typically means a low flat copay, often in the single digits to around $15 depending on the plan. Because CMS requires broad access within key therapeutic categories and generic ezetimibe is inexpensive relative to brand pricing, plans generally have little reason to restrict it.

Brand-name Zetia, where it still appears on a formulary, is usually placed on a preferred or non-preferred brand tier with meaningfully higher cost sharing, and some plans have dropped brand Zetia from the formulary entirely once a generic became available, directing members to the generic instead. CMS permits this kind of generic substitution as long as a therapeutically equivalent option remains covered.

Because these details are set by each plan sponsor and filed annually with CMS, the only reliable way to know current tier placement and cost sharing for a specific plan is to check that plan's current formulary through the Medicare Plan Finder or the plan's own published documents, and to confirm the plan year, since formularies can change between years.

Prior authorization and step therapy

Prior authorization on generic ezetimibe is not the norm across MA-PD plans, though some plans do apply it, particularly to confirm a hyperlipidemia diagnosis or document statin use, intolerance, or contraindication. When a plan requires prior authorization, expect the criteria to ask for a documented lipid disorder diagnosis, evidence that a moderate- or high-intensity statin was tried or is contraindicated, and LDL cholesterol still above the patient's individualized target.

Some plans apply step therapy, requiring documentation of a prior statin trial (or a documented reason a statin could not be used) before covering ezetimibe. This step is permitted under CMS's Part D step-therapy framework, provided plans meet notice and clinical-evidence requirements. In practice this rarely delays care in a meaningful way, because most patients started on ezetimibe have already tried a statin as first-line therapy, per longstanding cardiology guideline recommendations; the prescriber typically just needs to document that history.

Patients with a documented, specific adverse reaction to one or more statins (for example, muscle symptoms with a clear temporal relationship, or lab-confirmed hepatotoxicity) generally have the strongest basis for a step-therapy override, and patients with homozygous sitosterolemia should not be subject to a statin-trial requirement at all, since statins are not indicated for that condition and ezetimibe has its own standalone FDA approval there.

Federal regulation sets prior authorization turnaround at up to 72 hours for standard requests and 24 hours for requests marked expedited because a delay could jeopardize the enrollee's health, under 42 CFR Part 423's coverage determination timelines. Confirm current timelines directly, since regulatory text is periodically revised.

Appealing a denial

If a plan denies coverage of ezetimibe (generic or brand), Medicare Advantage appeals follow a defined, sequential process under 42 CFR Part 423, Subpart M:

1. Plan redetermination. File within 60 days of the denial notice. The plan generally must decide within 7 calendar days for a standard request or 72 hours if expedited. Include the denial letter, relevant lipid panel results, and clinical notes documenting diagnosis and any statin history.
2. Independent Review Entity (IRE). If the plan upholds its denial, the case moves to the CMS-contracted independent reviewer for a fresh clinical look, again on a standard or expedited timeline.
3. Administrative Law Judge hearing (OMHA). Available once a minimum dollar amount in controversy is met and the IRE has upheld the denial.
4. Medicare Appeals Council review.
5. Federal district court, available above a higher dollar threshold.

Federal oversight bodies have reported that a meaningful share of Medicare Advantage prior authorization denials are overturned when beneficiaries pursue an appeal, though the exact overturn rate varies by report and drug category and should be checked against the original oversight publication rather than repeated as a fixed statistic. The practical takeaway that does hold up: for an inexpensive, guideline-supported generic like ezetimibe, a denial is more often a documentation or claims-processing issue than a genuine clinical coverage dispute, which is why pursuing at least the first appeal step is usually worthwhile before assuming the drug is not covered.

Where ezetimibe fits among non-statin LDL-lowering options

Ezetimibe is one of several non-statin options Part D plans cover for LDL lowering, alongside PCSK9 inhibitor injectables (alirocumab, evolocumab), bempedoic acid, and inclisiran (administered under Part B rather than Part D because it requires in-office injection). Cardiology guidance has generally positioned ezetimibe as the first non-statin add-on to try, ahead of the costlier injectable and newer oral options, when statin therapy alone does not bring LDL to target. Generic ezetimibe's combination of low cost, oral dosing, and comparatively light prior authorization burden is the practical reason it tends to be favorably placed on formularies relative to these other classes, independent of any single outcomes number. Cardiovascular outcomes evidence for ezetimibe added to a statin comes from a large randomized trial in patients with recent acute coronary syndrome; the specific magnitude of benefit reported in that trial should be verified against the original publication before it is quoted to a patient, since secondary summaries of it are inconsistent.

Special cost situations

Beneficiaries with the Part D Low-Income Subsidy ("Extra Help") pay sharply reduced, capped copays for covered generics, which in practice can make generic ezetimibe close to free at the pharmacy counter; the exact capped amount is set annually by CMS and should be confirmed for the current year rather than assumed. Dual-eligible beneficiaries (Medicare and Medicaid) are auto-enrolled in a benchmark plan if they do not choose one, and these benchmark plans must cover CMS-required drug classes, which include ezetimibe's category; a dual-eligible beneficiary whose assigned plan does not cover it can request a plan change outside the standard annual enrollment window.

Manufacturer copay assistance cards cannot legally be used by anyone enrolled in Medicare Part D or Medicare Advantage, because federal anti-kickback rules bar manufacturer coupons for federal health program beneficiaries. For generic ezetimibe, this restriction matters less than it would for an expensive brand-only drug, since the generic's retail cost is already low for most patients; state pharmaceutical assistance programs and independent charitable foundations remain options for beneficiaries who still face a cost barrier.

A decision framework: what to check, in order

Use this sequence before assuming ezetimibe is or is not covered under a specific Medicare Advantage plan.

1. Confirm the formulation. Is the prescription for generic ezetimibe, brand Zetia, or a combination product (ezetimibe/simvastatin)? Coverage terms differ meaningfully between these.
2. Pull the plan's current formulary, not a general description of Medicare Advantage. Formularies are plan-specific and change by plan year. Note the exact tier and whether a prior authorization (PA) or step-therapy (ST) flag appears next to the drug.
3. If PA or ST is flagged, have the prescriber gather: the hyperlipidemia diagnosis code, current LDL value against goal, and a clear statement of statin history (drug, dose, duration, and outcome, tolerated, ineffective, or discontinued for a specific documented reason).
4. If the plan denies coverage, treat this as likely correctable rather than final for a low-cost generic. File a Level 1 redetermination within 60 days with the documentation above attached, and request expedited review only if a delay would genuinely jeopardize health.
5. If brand Zetia specifically is denied but generic ezetimibe is covered, the fastest resolution is usually switching the prescription to the generic, unless there is a documented reason (such as a true inactive-ingredient allergy) the generic cannot be used, simple preference is not an accepted justification.
6. If cost, not coverage, is the barrier, check Low-Income Subsidy eligibility and dual-eligible status before assuming a manufacturer coupon or full-price purchase is the only option; remember manufacturer coupons cannot legally be applied under Medicare.
7. If ezetimibe alone is not reaching LDL goal, that is a separate clinical conversation about escalating to a PCSK9 inhibitor, bempedoic acid, or inclisiran, each of which carries its own, generally higher, cost-sharing and prior authorization profile, and that decision belongs with the prescriber rather than the pharmacy benefit alone.

This sequence does not replace checking the specific plan's current documents, and it does not substitute for individualized medical or pharmacy-benefit advice.

A note on cost and coverage figures: specific dollar amounts, tier percentages, and appeal-outcome statistics in this space change year to year and by plan, and several figures often repeated online (exact prior authorization rates, exact appeal overturn percentages, and precise trial effect sizes) require verification against a current CMS formulary file or the original trial publication before they are presented to a patient as fixed facts. This article should be checked against current-year CMS Part D data by a reviewer before publication.